ClearPoint Neuro's stock fell 23.12% after its partner uniQure announced that a Huntington's disease treatment failed to meet a primary clinical endpoint in Phase I/II trials. The news raised concerns about the drug's effectiveness, prompting an investigation by Pomerantz LLP into possible securities fraud or misconduct by ClearPoint and its executives. Investors affected by the stock drop are encouraged to contact the law firm for potential class action participation.
ClearPoint Neuro's stock is trading at USD 9.41 on Pluang as of Oct 15, 2026 21:15 WIB, showing a 1.84% gain in the last day. The company's market cap stands at $281.86 million, reflecting its current valuation despite recent negative news. Trading volume is active with over 1 million shares exchanged, and the typical hold time on Pluang is 10 days.
